CAR-T – Page 5 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2022-01-11

CAR-T-cell therapy has the potential to replace chemoimmunotherapy for second-line treatment of patients with refractory or relapsed large B-cell lymphoma (LBCL)

In the ZUMA-7 trial, at a median follow-up of 24.9 months, patients randomly assigned to receive CAR T-cell therapy with axicabtagene ciloleucel, or axi-cell (Yescarta) had a median event-free survival (EFS) of 8.3 months, compared with 2 months for patients randomly assigned to standard-of-care chemoimmunotherapy, reported Frederick L. Locke, MD, from the Moffitt Cancer Center

No Comments InCAR-T

PIER MARIA FORNASARI
2022-01-11

Single injection of messenger RNA Can Be Used to Make CAR T cells in vivo and to attack fibrosis in heart failure .

Penn study reveals an easier, more scalable way to make a powerful immunotherapy An experimental immunotherapy can temporarily reprogram patients’ immune cells to attack a specific target via only a single injection of messenger RNA (mRNA), similar to the mRNA-based COVID-19 vaccines, according to a new study from researchers in the Perelman School of Medicine

No Comments InCAR-T

PIER MARIA FORNASARI
2022-01-02

Sloan Kettering Institute Scientists Retool CAR T Cells to Serve as ‘Micropharmacies’ for Cancer Drugs

Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient’s own immune cells to fight cancer. These treatments have energized cancer care, especially for people with certain types of blood cancers. Now, scientists at Memorial Sloan Kettering Cancer Center’s Sloan Kettering Institute (SKI) have developed new CAR T cells that can do something their

No Comments InCAR-T

PIER MARIA FORNASARI
2021-12-17

CAR-HEMATOTOX score: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Immunotherapy with so-called CAR-T cells has established itself for the treatment of various leukemias (blood cancer) and lymphomas (lymph gland cancer). A team led by Dr. Kai Rejeski and Prof. Marion Subklewe from the Medical Clinic III of the LMU Klinikum found that many patients suffer from a side effect that initially fell under the radar: a

No Comments InCAR-T

PIER MARIA FORNASARI
2021-12-16

Blockade or deletion of IFN-gamma reduces macrophage activation without compromising CAR T function in hematologic malignancies

Blood Cancer Discovery, a journal of the American Association for Cancer Research, has published a research article demonstrating a novel approach that may reduce a serious adverse effect associated with chimeric antigen receptor (CAR) T-cell therapy, a form of immunotherapy. This research was presented at the American Society of Hematology Annual Meeting in Atlanta, Georgia

No Comments InCAR-T

PIER MARIA FORNASARI
2021-12-11

Potentially Serious Side Effect Seen in Patient after CAR-T cell treatment for multiple myeloma

Mount Sinai scientists have become the first to report a potentially serious side effect related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma. Their findings were published as a case study in Nature Medicine in December. Multiple myeloma is a complex and incurable type

No Comments InCAR-T

PIER MARIA FORNASARI
2021-11-17

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy

Chimeric antigen receptor T-cell (CAR T) therapy has revolutionized the field of malignant hematology. CD19-targeted CAR T-cell therapy has resulted in effective, often durable, responses for chemotherapy-refractory B-cell lymphoma and B-acute lymphoblastic leukemia (B-ALL) in prospective clinical trials. CAR T cells against B-cell maturation antigen have also shown overall response rates in the range of

No Comments InCAR-T

PIER MARIA FORNASARI
2021-11-04

Children Hospital of Philadelphia Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers

In a breakthrough for the treatment of aggressive solid cancers, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach. Using the power of large data sets and advanced computational approaches,

No Comments InCAR-T

PIER MARIA FORNASARI
2021-06-01

Exploring CAR T-Cell Therapy to treat Breast Cancer

Peter MacCallum researchers are developing a potential new way to make CAR T-cell therapy more effective against breast cancer and other solid cancers. CAR T-cell therapy is a type of immunotherapy where a patient’s own immune cells are collected and reengineered, before being infused back into the patient to fight their cancer. But CAR T-cells

No Comments InCAR-T

PIER MARIA FORNASARI
2021-05-29

Smart CAR-T Cell Therapies for Solid Cancers Ready to Move Toward Clinical Trials

Immunotherapies that fight cancer have been a life-saving advancement for many patients, but the approach only works on a few types of malignancies, leaving few treatment options for most cancer patients with solid tumors. Now, in two related papers published April 28, 2021, in Science Translational Medicine, researchers at UCSF have demonstrated how to engineer smart immune cells

No Comments InCAR-T

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category CAR-T

CAR-T-cell therapy has the potential to replace chemoimmunotherapy for second-line treatment of patients with refractory or relapsed large B-cell lymphoma (LBCL)

Single injection of messenger RNA Can Be Used to Make CAR T cells in vivo and to attack fibrosis in heart failure .

Sloan Kettering Institute Scientists Retool CAR T Cells to Serve as ‘Micropharmacies’ for Cancer Drugs

CAR-HEMATOTOX score: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Blockade or deletion of IFN-gamma reduces macrophage activation without compromising CAR T function in hematologic malignancies

Potentially Serious Side Effect Seen in Patient after CAR-T cell treatment for multiple myeloma

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy

Children Hospital of Philadelphia Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers

Exploring CAR T-Cell Therapy to treat Breast Cancer

Smart CAR-T Cell Therapies for Solid Cancers Ready to Move Toward Clinical Trials